RNA test identifies large B-cell lymphoma subtypes: Lisa Rimsza, M.D.
About this episode
Lisa Rimsza, M.D., explains how Mayo Clinic Laboratories' unique PM3CX test can accurately define subtypes of large B-cell lymphoma. Precise diagnosis is critical to choosing appropriate chemotherapy for these cancers.
Speaker 2: (00:32)
Could you provide a brief background about yourself?
Speaker 2: (01:12)
Would you give us an overview of the PM3CX test?
Speaker 2: (03:02)
Which patients should have this testing?
Speaker 2: (05:14)
Is this test qualitative and RNA?
Speaker 2: (06:35)
After determining if it's primary mediastinal large B-cell lymphoma or diffuse large B-cell lymphoma, does the test identify the cell of origin?
Speaker 2: (08:09)
For patients diagnosed with diffuse large B-cell lymphoma, what are the treatment recommendations?
Speaker 2: (09:04)
Are there any other insights about this test that you'd like to share?
Get every episode summarized
Each time Answers from the Lab publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
Hosts & guests
No transcript yet
This episode has not been transcribed. Request it and it moves to the front of the queue.
More episodes
More from Answers from the Lab
Unique Assays Advance Care of Complex Autoimmune Skin Conditions
Answers from the Lab
Digital Advances: What’s Next for Clinical Diagnostics?
Answers from the Lab
Preeclampsia Test Helps Extend Pregnancy to Improve Outcomes
Answers from the Lab
Breakthrough Test Enhances Peripheral Neuropathy Care and Research
Answers from the Lab